Synergistic Biotherapeutic Agent Delivery Systems

The invention integrates nanoporous implantable canisters with cutting-edge technologies like AI, IoT, blockchain, and advanced materials to create a new generation of personalized, adaptive, and efficient biotherapeutic agent delivery systems.

The original patent provided a biocompatible, nanoporous device for delivering cellular and biotherapeutic agents. However, it lacked real-time monitoring, personalized medicine capabilities, and advanced integration with other technologies. The new inventive concept addresses these limitations by combining the patented nanoporous canister with AI, IoT, blockchain, and novel materials to create a more powerful, adaptive, and efficient system.

The synergistic biotherapeutic agent delivery system comprises a nanoporous canister integrated with an AI-powered sensor for real-time monitoring of agent release, a blockchain-secured, patient-specific biotherapeutic agent, and IoT-enabled monitoring to track agent efficacy. The system can be further enhanced with modular, 3D-printed, nanoscale-patterned surfaces for tissue integration and machine learning algorithms for predicting optimal agent release profiles. The hybrid, implantable canister combines a nanoporous, metallic outer shell with a polymeric, nanoscale-patterned inner surface to enhance agent stability and provide structural support.

The new inventive concept's integration of AI, IoT, blockchain, and advanced materials with the patented nanoporous canister provides a non-obvious and novel solution for personalized, adaptive, and efficient biotherapeutic agent delivery. The inventive step lies in the synergistic combination of these distinct technologies to create a more powerful system.

Alternative embodiments may include variations in the AI algorithm, IoT connectivity, blockchain security, and materials used. Additionally, the system could be adapted for different types of biotherapeutic agents, tissues, or diseases, ensuring broad conceptual coverage.

The synergistic biotherapeutic agent delivery system has significant commercial potential in the fields of personalized medicine, tissue engineering, and regenerative medicine. The target market includes pharmaceutical companies, medical device manufacturers, and healthcare providers seeking to improve treatment outcomes and patient care.